In Vitro and In Vivo Antiviral Studies of New Heteroannulated 1,2,3-Triazole Glycosides Targeting the Neuraminidase of Influenza A Viruses
Authors:
- Omnia KutkatOKOmnia Kutkat
- Ahmed KandeilAhmed Kandeil
- Yassmin MoatasimYMYassmin Moatasim
- Yaseen A. M. M. ElshaierYEYaseen A. M. M. Elshaier
- Wael A. El-SayedWEWael A. El-Sayed
- Samir T. GaballahSGSamir T. Gaballah
- Ahmed El TaweelATAhmed El Taweel
- Mina Nabil KamelMKMina Nabil Kamel
- Mohamed El SayesMSMohamed El Sayes
- Mohammed A. RamadanMRMohammed A. Ramadan
- Rabeh El-SheshenyRabeh El-Shesheny
- Farouk M. E. Abdel-MegeidFAFarouk M. E. Abdel-Megeid
Open Access
- 14 March 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (3) , 351
Abstract
There is an urgent need to develop and synthesize new anti-influenza drugs with activity against different strains, resistance to mutations, and suitability for various populations. Herein, we tested in vitro and in vivo the antiviral activity of new 1,2,3-triazole glycosides incorporating benzimidazole, benzooxazole, or benzotriazole cores synthesized by using a click approach. The Cu-catalyzation strategy consisted of 1,3-dipolar cycloaddition of the azidoalkyl derivative of the respective heterocyclic and different glycosyl acetylenes with five or six carbon sugar moieties. The antiviral activity of the synthesized glycosides against wild-type and neuraminidase inhibitor resistant strains of the avian influenza H5N1 and human influenza H1N1 viruses was high in vitro and in mice. Structure–activity relationship studies showed that varying the glycosyl moiety in the synthesized glycosides enhanced antiviral activity. The compound (2R,3R,4S,5R)-2-((1-(Benzo[d]thiazol-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 9c) had a 50% inhibitory concentration (IC50) = 2.280 µM and a ligand lipophilic efficiency (LLE) of 6.84. The compound (2R,3R,4S,5R)-2-((1-((1H-Benzo[d]imidazol-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate had IC50 = 2.75 µM and LLE = 7.3 after docking analysis with the H5N1 virus neuraminidase. Compound 9c achieved full protection from H1N1 infection and 80% protection from H5N1 in addition to a high binding energy with neuraminidase and was safe in vitro and in vivo. This compound is suitable for further clinical studies as a new neuraminidase inhibitor.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (HHSN272201400006C)
- National Research Centre (12010125)
This publication has 44 references indexed in Scilit:
- Discovery and Extensive in Vitro Evaluations of NK-HDAC-1: A Chiral Histone Deacetylase Inhibitor as a Promising LeadJournal of Medicinal Chemistry, 2012
- Structure–activity relationship studies of SYA 013, a homopiperazine analog of haloperidolBioorganic & Medicinal Chemistry, 2012
- Influenza M2 proton channelsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activitiesBioorganic & Medicinal Chemistry Letters, 2006
- Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza VirusesJournal of Virology, 2006
- C-Glycoside Clustering on Calix[4]arene, Adamantane, and Benzene Scaffolds through 1,2,3-Triazole LinkersThe Journal of Organic Chemistry, 2006
- “Click Chemistry” Inspired Synthesis of pseudo-Oligosaccharides and Amino Acid GlycoconjugatesThe Journal of Organic Chemistry, 2005
- Synthesis of Fluorosugar Analogues of 2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole as Antivirals with Potentially Increased Glycosidic Bond StabilityJournal of Medicinal Chemistry, 2000
- Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms Haemophilus influenzae and Moraxella catarrhalisJournal of Medicinal Chemistry, 2000
- Synthesis and Antiviral Activity of 6-Benzyl Analogs of 1-[(2-Hydroxyethoxy)methyl]-5-(phenylthio)thymine (HEPT) as Potent and Selective Anti-HIV-1 AgentsJournal of Medicinal Chemistry, 1995